신경통 치료 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Neuralgia Treatment Market, valued at USD 2.4 billion in 2024, is set to experience substantial growth, with a projected CAGR of 7.7% from 2025 to 2034. This growth is primarily driven by the increasing prevalence of neurological disorders and advancements in awareness, diagnosis, and treatment options.

The rising incidence of neurological conditions, particularly various forms of neuralgia, is a key factor fueling market expansion. As awareness surrounding these disorders grows, more individuals are seeking early diagnosis and treatment. Public awareness campaigns and improved diagnostic capabilities have played a significant role in detecting neuralgia at earlier stages, driving demand for therapies that target conditions like trigeminal neuralgia, postherpetic neuralgia, and other forms of nerve-related pain.

The market is segmented by various neuralgia conditions, including trigeminal neuralgia, postherpetic neuralgia, occipital neuralgia, and others. Among these, trigeminal neuralgia is expected to see the highest growth, with a projected CAGR of 7.9%, reaching USD 2.1 billion by 2034. Trigeminal neuralgia, one of the most common types of neuralgia, especially affects older populations and can severely impact daily activities and overall quality of life. This has led to increased demand for better treatment options, further propelling market growth.

From the perspective of end-users, hospitals are projected to drive substantial growth in the neuralgia treatment market. With advanced diagnostic tools like MRI and CT scans, hospitals remain the preferred setting for comprehensive diagnosis and treatment. These cutting-edge technologies enable healthcare providers to accurately identify different types of neuralgia, ensuring that patients receive the most effective and targeted treatments. The ability to offer precise diagnostic capabilities makes hospitals the most trusted and reliable environments for treating complex neurological conditions, thus securing their dominance in the market.

In the U.S., the neuralgia treatment market is expected to see robust growth during the forecast period. The country's advanced healthcare infrastructure, featuring state-of-the-art imaging technologies, surgical techniques, and pharmacological innovations, continues to support its market leadership. With an aging population that is particularly vulnerable to conditions like trigeminal and postherpetic neuralgia, the demand for effective treatments is escalating. Furthermore, favorable reimbursement policies and significant investments in research and development by major pharmaceutical companies are contributing to the market's expansion, ensuring that the U.S. remains a key player in the global neuralgia treatment landscape.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of neurological disorders
    • 3.2.1.2 Advancements in pain management technologies
    • 3.2.1.3 Increase in awareness and diagnosis rates
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Reimbursement scenario
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Future market trends

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Surgical procedures
  • 5.2.1 Radiofrequency thermal lesioning
  • 5.2.2 Stereotactic radiosurgery
  • 5.2.3 Microvascular decompression
  • 5.2.4 Other surgical procedures
• 5.3 Medications
  • 5.3.1 Anticonvulsants
  • 5.3.2 Antidepressants
  • 5.3.3 Other medications

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Trigeminal neuralgia
• 6.3 Postherpetic neuralgia
• 6.4 Occipital neuralgia
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Clinics
• 7.4 Ambulatory surgical centers
• 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AA pharma
• 9.2 astellas
• 9.3 Biogen
• 9.4 Eli Lilly
• 9.5 Johnson & Johnson
• 9.6 Medtronic
• 9.7 NOVARTIS
• 9.8 PACIRA BIOSCIENCES
• 9.9 Pfizer
• 9.10 Siemens Healthineers